In the 1970s, an unknown virus was suspected for documented cases of transfusion-
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …

Background. Although guidelines recommend that people who inject drugs (PWID) should
not be excluded from hepatitis C (HCV) treatment, some services remain reluctant to treat …

Background In phase 2 studies, treatment with the all-oral combination of the nucleotide
polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of …

The recommended treatment for patients with chronic hepatitis C, pegylated interferon-α
(PEG-IFN-α) plus ribavirin (RBV), does not provide sustained virologic response (SVR) in all …

Summary Background Treatment of HBeAg-positive patients with chronic hepatitis B is not
effective in most. A combination of immunomodulatory pegylated interferon alfa-2b and …

BACKGROUND & AIMS: We recently identified a polymorphism upstream of interleukin (IL)-
28B to be associated with a 2-fold difference in sustained virologic response (SVR) rates to …

Thrombocytopenia (platelet count< 150,000/μL) is a common complication in patients with
chronic liver disease (CLD) that has been observed in up to 76% of patients. Moderate …

Interferon and ribavirin combination therapy for chronic hepatitis C produces a number of
well‐described side effects that are dominated by fatigue, influenza‐like symptoms …

The treatment of hepatitis C has dramatically improved over the past decade. Unlike any
other chronic viral infection, a significant proportion of patients with chronic hepatitis C can …

Aims The Korean Association for the Study of the Liver (KASL) Practice Guidelines for
Management of Hepatitis C were first established in 2004, and revised in 2013, when direct …